Skip to main content
SpringerLink
Log in

Gutartige Prostatavergrößerung

Klinik, Diagnostik und Therapie des benignen Prostatasyndroms

Benign prostatic enlargement: symptoms, diagnostics and therapy

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Das benigne Prostatasyndrom (BPS) zählt weltweit zu den häufigsten Krankheitsbilder des Mannes. Da die Inzidenz mit dem Alter zunimmt, steigt durch den demografischen Wandel unserer Gesellschaft auch die Prävalenz. Ein individualisierter Therapieansatz ist wegen der unterschiedlichen Ausprägung der Symptomatik zwingend erforderlich. Was wann getan werden sollte, lesen Sie in diesem Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European Urology. 2015;67:1099–1109

    Article  Google Scholar 

  2. Oelke M, Kuczyk MA, Herrmann TR. Pharmacological treatment of benign prostatic hyperplasia. Der Urologe Ausg A. 2009;481365–75; quiz 76–7

    Article  CAS  Google Scholar 

  3. Gratzke C, Stief CG. Male lower urinary tract symptoms: the role of the prostate. MMW Fortschr Med. 2013;155(14):34

    Article  Google Scholar 

  4. Weinhold P, Magistro G, Strittmatter F, Herlemann A, Stief CG, Gratzke C et al. Etiology and diagnostics of the benign prostate syndro. MMW Fortschr Med. 2013;155(14):35–8

    Article  Google Scholar 

  5. Chapple C. Overview on the lower urinary tract. Handbook of experimental pharmacology. 2011;202:1–14

    Article  CAS  Google Scholar 

  6. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. European urology. 2011;59:342–52

    Article  CAS  Google Scholar 

  7. Bschleipfer T, Wagenlehner F, Weidner W. Etiology and pathogenesis of overactive bladder. Der Urologe Ausg A. 2011;50:477–80

    Article  CAS  Google Scholar 

  8. Roosen A, Gratzke C, Herrlemann A, Magistro G, Strittmatter F, Weinhold P et al. Etiology and pathophysiology of benign prostate hyperplasia. Der Urologe Ausg A. 2013;52:186–92.

    Article  CAS  Google Scholar 

  9. Knupfer S, Hamann M, Naumann CM, Melchior D, Junemann KP. Therapy-refractory overactive bladder: alternative treatment approaches. Der Urologe Ausg A. 2011;50:806–9

    Article  CAS  Google Scholar 

  10. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thuroff JW. Epidemiology and etiology of overactive bladder. Der Urologe Ausg A. 2003;42:776–86

    Article  CAS  Google Scholar 

  11. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50:1306–14; discussion 14–5.

    Article  Google Scholar 

  12. Gravas S, Cornu, J. N., Drake, M. J., Gacci, M., Gratzke, C., Herrmann, T. R. W., Madersbacher, S., Mamoulakis, C., Tikkinen, K. A. O. Management of Non-neurogenic Male LUTS. EAU Guidelines Edn presented at the EAU Annual Congress Copenhagen 2018 ISBN 978-94-92671-01-1. 2018

  13. Barry MJ, Fowler FJ, Jr., O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. The Journal of Urology. 1992;148:1549–57; discussion 64

    Article  CAS  Google Scholar 

  14. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International Consultation on New Developments in Prostate C et al. Evaluation and treatment of lower urinary tract symptoms in older men. The Journal of Urology. 2013;189(1 Suppl):S93–S101

    CAS  PubMed  Google Scholar 

  15. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581–9

    Article  CAS  Google Scholar 

  16. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0, 2018, AWMF Registernummer: 043/022OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (abgerufen am: 13.03.2019).

  17. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology. 1998;51(4A Suppl):19–22

    PubMed  Google Scholar 

  18. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. European urology. 2004;46:753–9

    Article  CAS  Google Scholar 

  19. Oelke M, Hofner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. European urology. 2007;52:827–34

    Article  Google Scholar 

  20. Reynard JM, Yang Q, Donovan JL, Peters TJ, Schafer W, de la Rosette JJ et al. The ICS ‘BPH’ Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82:619–23

    Article  CAS  Google Scholar 

  21. Clement KD, Burden H, Warren K, Lapitan MC, Omar MI, Drake MJ. Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction. Cochrane Database Syst Rev. 2015:CD011179

  22. Netto NR, Jr., de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology. 1999;53:314–6

    Article  Google Scholar 

  23. Strittmatter F, Madersbacher S, Stief CG, Gratzke C. Medical therapy of lower urinary tract symptoms corrected. Der Urologe Ausg A. 2012;51:1125–36

    Article  CAS  Google Scholar 

  24. Berges R. Treatment of LUTS in BPS. When and when not to administer pills? Der Urologe Ausg A. 2009;48:257–63

    Article  CAS  Google Scholar 

  25. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. The Journal of Urology. 2008;179:616–21; discussion 21

    Article  CAS  Google Scholar 

  26. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European urology. 2010;57:123–31

    Article  CAS  Google Scholar 

  27. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61:791–6

    Article  Google Scholar 

  28. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–28

    Article  CAS  Google Scholar 

  29. Andersson KE. LUTS treatment: future treatment options. Neurourology and urodynamics. 2007;26(Suppl 6):934–47

    Article  CAS  Google Scholar 

  30. Madersbacher S. Combination therapy of benign prostate syndrome/lower urinary tract symptoms. Der Urologe Ausg A. 2013;52:212–8

    Article  CAS  Google Scholar 

  31. Cantrell MA, Baye J, Vouri SM. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy. 2013;33:639–49

    Article  CAS  Google Scholar 

  32. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology. 2012;61:994–1003

    Article  CAS  Google Scholar 

  33. Ahmad M, Khan H, Aminullah, Masood I, Masood W, Malik A. Comparison Of Bipolar And Monopolar Cautry Use In Turp For Treatment Of Enlarged Prostate. J Ayub Med Coll Abbottabad. 2016;28:758–61

    PubMed  Google Scholar 

  34. Magistro G, Stief CG, Gratzke C. Minimally invasive treatment of benign prostatic hyperplasia. Der Urologe Ausg A. 2016;55:1419–32.

    Article  CAS  Google Scholar 

  35. Gratzke C, Strittmatter F, Reich O, Bachmann A, Stief CG, Seitz M. Surgical treatment of male lower urinary tract symptoms (LUTS). Der Urologe Ausg A. 2012;51:1297–306; quiz 307

    Article  CAS  Google Scholar 

  36. Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. European urology. 2010;58:384–97

    Article  Google Scholar 

  37. Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg. 2007;94:1201–8

    Article  CAS  Google Scholar 

  38. Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(st) Century. Am J Clin Exp Urol. 2015;3:36–42

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Campus Großhadern, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistr. 15, D-81377, München, Deutschland

    Alexander Tamalunas,  Giuseppe Magistro,  Tobias Grimm,  Jan-Friedrich Jokisch, Thilo Westhofen, Melanie Schott,  Christian G. Stief &  Philipp Weinhold

Authors
  1. Alexander Tamalunas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Magistro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan-Friedrich Jokisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thilo Westhofen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Melanie Schott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philipp Weinhold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Tamalunas.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tamalunas, A., Magistro, G., Grimm, T. et al. Klinik, Diagnostik und Therapie des benignen Prostatasyndroms. MMW - Fortschritte der Medizin 161, 50–57 (2019). https://doi.org/10.1007/s15006-019-0017-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0017-7

Keywords

Search

Navigation